Effect of bevacizumab combined with sintilimab on hepatoma markers and apoptosis factors of patients with primary liver cancer
OBJECTIVE To investigate the influence of bevacizumab combined with sintilimab on hepatoma markers and apoptosis factors of patients with primary liver cancer.METHODS A total of 80 patients with primary liver cancer admitted to the Department of Infectious Diseases of the Affiliated Hospital of Putian University from January 2022 to January 2024 were selected and divided into the control group and the observation group by the random number table method,with 40 cases in each group.The control group was treated with sintilimab,and the observation group was treated with bevacizumab combined with sintilimab.The total effective rate of primary liver cancer treatment,the incidence of adverse reactions,the levels of hepatoma markers(G73,AFP-L3 and AFP)and apoptosis factors(sFas,sFasL and Caspase-3)before and after the treatment of two groups were compared.RESULTS The total effective rate of primary liver cancer treatment of the observation group was significantly higher than that of the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).There was no significant difference in the levels of the hepatoma markers and apoptosis factors between the two groups before the treatment(P＞0.05).The hepatoma markers,sFas and sFasL levels of the observation group after the treatment of four courses were significantly lower than those of the control group(P＜0.05),and the level of Caspase-3 was significantly higher than that of the control group(P＜0.05).CONCLUSION Bevacizumab combined with sintilimab has a good clinical effect in the treatment of patients with primary liver cancer,which can significantly improve the levels of hepatoma markers and apoptosis factors,and has a high application value in the treatment of primary liver cancer.
NETL
NSTL
万方数据
